Jerash pharmaceuticals

What Jerash pharmaceuticals does

Jerash Pharmaceuticals is a privately held pharmaceutical manufacturer established in 2005 in Amman, Jordan, operating as part of the family-owned Khraim Group (pharmaceutical heritage dating to 1965). The company specializes in liquid and semisolid dosage forms, topical emulsions, intranasal solutions, and hospital disinfectants, organized across six product categories with a portfolio of approximately 30+ SKUs covering dermatology, respiratory, pediatric, analgesic, and antiseptic/anticoagulant therapy areas. Its most strategically significant product is Joxane, the first biosimilar of LMWH Enoxaparin approved in the Jordan market (2019 launch per company history, 2022 per product-launch record), available in three strengths for venous thromboembolism prophylaxis and treatment.

The company's core technology centers on GMP-certified formulation and analytical capabilities aligned with USA, European, and British Pharmacopoeias, following JFDA, USFDA, GCC, and ICH guidelines. Manufacturing is supported by dedicated R&D, Regulatory Affairs, Quality Assurance/Quality Control, and Engineering functions, with calibration/validation activities and HVAC/water/waste treatment systems managed in-house. The group structure provides vertical integration: Khraim Drug Store (sister, est. 1971) acts as the distribution and agency channel for ethical pharmaceuticals in Jordan and neighboring countries, and Aleiman Laboratories (subsidiary) produces GMP-certified, ISO 9001 and ISO 13485 certified medicated cosmetics and hospital disinfectants.

Jerash serves medical clinics, hospitals, pharmacies, and end-use patients in Jordan and the wider Middle East. Its go-to-market leverages the captive Khraim Drug Store channel, supplemented by direct sales/marketing functions and partnerships (notably with Al-Eman Factory during the COVID-19 pandemic for antiseptic donations). Revenue mechanics are conventional pharmaceutical manufacturing — sell-through to distributors, pharmacies, and institutional healthcare buyers — with no public pricing, no disclosed revenue, and no public or institutional capital structure. The company explicitly positions itself as a niche product manufacturer for niche markets, including the higher-value biosimilar segment via Joxane.

Name

Jerash pharmaceuticals

Legal name

Jerash Pharmaceuticals

Website

https://jerashpharma.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

101–250 employees

Short description

Jerash Pharmaceuticals is a Jordan-based, privately held pharmaceutical manufacturer (est. 2005) producing liquid, semisolid, topical, intranasal, and disinfectant products, plus the Joxane biosimilar Enoxaparin injection, for pharmacies, hospitals, and clinics in Jordan and the Middle East.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

Keywords

• Pharmaceutical manufacturing
• Generic pharmaceuticals
• Biosimilar drugs
• Hospital disinfectants
• Topical medications

Headquarters

HQ city

Amman

HQ country

Jordan

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels1 record

Core offering

Jerash Pharmaceuticals manufactures oral liquids, semisolids, topical emulsions, tablet drugs, intranasal solutions, and hospital disinfectants for medical and clinical use. The company is part of the Khraim Group, established in 2005 in Amman, Jordan, with formulation and analytical capabilities aligned to USA, European, and British Pharmacopoeias and compliant with JFDA, USFDA, GCC, and ICH guidelines. Its flagship offering is Joxane®, the first biosimilar of LMWH Enoxaparin in the Jordan market.

Product overview

Jerash Pharmaceuticals is a pharmaceutical manufacturing company established in Amman, Jordan in 2005, specializing in liquid and semisolid dosage forms as well as hospital disinfectants. The company operates under the Khraim Group and focuses on niche products for niche markets. Their product portfolio spans six main categories: Oral Liquid Products (including syrups, suspensions, and drops like Dilamuc, Jos-Pan, Pediafast, Jofen, Allezine, Jofamin, and Amrox), Semisolid Products (creams, ointments, and gels such as Algesal, Beta-cal, Jedara, S-Cure, FixoDerm, Dermoheal, Emacort, ClobeDerm, Betaroid, Flocinal, Colisal, and Micozole), Topical Solutions (including Bald X for hair growth and Killy-Lice shampoo), Tablet Drugs (Convumax for epilepsy), Intranasal Solutions (Free breath nasal solutions), and their flagship biosimilar product Joxane® (Enoxaparin injection for anticoagulation therapy). The company operates GMP-certified manufacturing facilities and maintains international quality standards.

Differentiator

Problem solved

Functional benefit

Brands

• Joxane®: Enoxaparin Sodium Injection product line including Joxane 4000, 6000, and 8000 anti-Xa IU formulations for prophylaxis and treatment of venous thromboembolism

Products and services

• Joxane® (Enoxaparin Sodium Injection) Joxane is a biosimilar Enoxaparin Sodium injection available in three strengths (4000, 6000, and 8000 anti-Xa IU) used for prophylaxis and treatment of venous thromboembolism, treatment of unstable angina, STEMI, and blood clot prevention in extracorporeal circulation during haemodialysis. Targeted at hospitals, clinics, and healthcare providers requiring anticoagulant therapy.
• Convumax Tablet (Topiramate) Topiramate tablet in multiple strengths (100, 200, 250, 500 mg) for antiepileptic treatment. Targeted at pharmacies, hospitals, and patients requiring epilepsy management therapy.
• Oral Liquid Products (Dilamuc Syrup, Jos-Pan Syrup, Pediafast Drops and Syrup, Jofen Suspension and Oral Drops, Allezine Oral Solution, Jofamin Syrup, Amrox Liquid) A range of oral liquid pharmaceutical products including syrups, suspensions, and drops covering respiratory, pediatric, anti-allergic, antihistamine, anti-inflammatory, and secretolytic therapies. Targeted at pharmacies, pediatric care providers, and patients requiring liquid-form medications.
• Semisolid Products (Algesal Baume Cream, Algesal Cold Gel, Beta-cal Ointment, Jedara Cream, S-Cure Ointment, FixoDerm Cream, Dermoheal Cream, Emacort Ointment, ClobeDerm Ointment, Betaroid Ointment, Flocinal Cream, Colisal Cool Gel, Micozole Oral Gel) A portfolio of dermatological creams, ointments, and gels for treatment of musculoskeletal pain, warts, dermatoses, psoriasis, eczema, lichen planus, discoid lupus erythematosus, dry/cracked skin, stretch marks, teething, and oral candidiasis. Targeted at pharmacies, dermatologists, and patients with skin, musculoskeletal, or oral conditions.
• Topical Solutions (Bald X 5% and 2%, Killy-Lice Shampoo, Emacort Topical Solution) Topical pharmaceutical solutions including minoxidil formulations for hair growth, permethrin-based shampoo for lice treatment, and salicylic acid/dexamethasone solutions for inflammatory skin conditions. Targeted at pharmacies, dermatology clinics, and patients requiring hair loss, lice, or anti-inflammatory topical therapy.
• Intranasal Solutions (Free Breath Solution, Free Breath Solution with Eucalyptus) NaCl-based intranasal solutions for gentle nasal cleaning in babies and children, with an eucalyptus variant. Targeted at pharmacies, pediatric care providers, and parents of infants/children.

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Al-Eman Factory for Antiseptics and DisinfectantsminorStrategic or Co-development PartnerCooperation during Corona pandemic to donate antiseptic and disinfectant products for hands and surfaces to medical clinics. Jerash Pharmaceuticals worked with Al-Eman Factory to support the local community and medical sector during the pandemic.
• Khraim Drug StorecoreChannel Partner/ Reseller/ DistributorAgent for ethical pharmaceuticals and medical supplies representing multinational companies in Jordan and neighboring countries. Part of the same Khraim Group as Jerash Pharmaceuticals, established in 1971.

Scale indicators2 records

Recent moves5 records

Expansion highlights3 records

Regional players

• Tabuk Pharmaceuticals: Saudi Arabian manufacturer of branded generics, biologics and biosimilars serving the GCC and broader MENA region; comparable on therapeutic breadth and biosimilar ambition but operates from a different primary geography.
• Eva Pharma: Egyptian pharmaceutical manufacturer with a wide generic portfolio plus newer biologics and biosimilars capability, exporting across MENA and Africa; comparable to Jerash on biosimilar ambition and broad therapeutic coverage but operates from a larger regional base.
• Julphar (Gulf Pharmaceutical Industries): UAE-based generic pharmaceutical manufacturer with broad dosage-form portfolio (liquids, semisolids, injectables) and operations across MENA, CIS and Asia; comparable to Jerash on regional generic-pharma model and manufacturing profile.
• SPIMACO Addwaeih: Saudi Arabia-headquartered pharmaceutical manufacturer producing generics across liquids, semisolids, topicals, tablets and injectables for the GCC and MENA markets; highly comparable in product form-factor and geographic footprint.

Direct peers

• Hikma Pharmaceuticals: Jordan-headquartered multinational generic and specialty pharmaceutical manufacturer with a portfolio spanning oral solids, injectables and biosimilars; directly comparable to Jerash on geography, dosage-form focus and therapeutic breadth, but at substantially greater scale.
• Dar Al Dawa Pharmaceuticals: Jordanian pharmaceutical manufacturer producing generics across multiple dosage forms including liquids, semisolids, topicals and injectables for local and regional markets; the closest Jordanian competitor to Jerash in portfolio shape and regulatory positioning.
• Jordan Pharmaceutical Manufacturing (JPM): Long-established Jordanian manufacturer of generic medicines covering tablets, syrups, semisolids and injectables, supplying local and MENA markets; comparable to Jerash on product mix, regulatory footprint and domestic-market positioning.

Broad incumbents

• Cipla: Indian multinational with a broad generics portfolio spanning respiratory, dermatology, cardiovascular and biosimilars, with established MENA commercial reach; functions as a broad incumbent benchmark for pricing and distribution breadth versus Jerash.
• Aurobindo Pharma: Large Indian generic and biosimilar manufacturer with extensive sterile injectable capacity, including LMWH Enoxaparin injectables; represents the high-volume/cost-competitive incumbent that Jerash's biosimilar and injectable strategy must compete against on price in tenders.

Emerging players

• Cipla BioTec (biosimilar unit) / Reliance Life Sciences: Players developing biosimilar Enoxaparin and adjacent biologics for emerging markets; comparable to Jerash's Joxane effort on product focus, though operating with larger capital bases and broader biologic pipelines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/jerash-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jerash pharmaceuticals